7 Tales from 20 years of Deep Tech Life Science Venture Capital Investment

Sebastien Groyer - A Venture Capitalist turned Serial Entrepreneur

In 16 years of supporting life science companies in raising capital and structuring deals with the pharma industry, I never felt that venture capital exists in abundance on the European market.

It always looked to me that the market is very VC-friendly on the European stage - plenty of teams and technology meet with a scarcity of available funds.

This was the reason to start the LSG2G Lunch MeetUps in June 2017. I remember our first meetup with 15 Life Science Enthusiasts like Pharma Business Developer, Life Science Investors, Life Science Entrepreneurs, and Service Partners. We discussed the state of Investments in Biotech in Europe.

As the first meetup was well received, the LSG2G Partners organized one every three months, an investment conference, and during the pandemic, created a podcast.

Availability of Venture Capital in Europe